Anagin, founded in Indianapolis, is dedicated to developing first-in-class therapies for neuropsychiatric disorders such as Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), depression, neuropathic pain, Alzheimer's disease, and Parkinson's disease. The company's core mission is to offer hope and improve the quality of life for millions of patients worldwide by addressing these debilitating conditions with innovative and targeted treatments.
Notable individuals associated with Anagin include experts in neuroscience and pharmacology who drive the company's research and development. The company has garnered attention for its pioneering approach and potential impact on mental health and neurodegenerative diseases. Anagin's achievements include significant advancements in preclinical studies, positioning it as a promising player in the biotech industry focused on neuropsychiatric therapeutics.
